May 2013 Blog Posts (19)

The Science Behind the 2013 Annual ASCO Meeting


Medical oncologist Douglas Yee, MD, a nationally recognized breast cancer researcher and chair of the ASCO 2012 - 2013 Scientific Program Committee, presents and discusses the various elements of this year's ASCO program.

Yee's laboratory research on the growth regulation of tumors provided the foundation for the development of new anti-cancer drugs…


Added by Editorial Team on May 31, 2013 at 12:30pm — No Comments

"Building Bridges to Conquer Cancer" Is the Theme of this Year's Annual Meeting of the American Society of Clinical Oncology (ASCO)

“Fifty years of modern oncology has delivered dramatic progress, offering our patients better treatments, more cures and a better quality of life during and after therapy," said Bruce J. Roth, MD, Chair of the ASCO’s Cancer Communications Committee. “Studies being presented at this year’s Annual Meeting of the American Society of Clinical Oncology embody a new era of precision medicine, in which we’re taking better aim at vital targets on cancer and immune cells. Several studies also…


Added by Editorial Team on May 31, 2013 at 9:00am — No Comments

ASCO's 2013 Educational Program

In this program, Antoinette R. Tan, MD, a medical oncologists at the The Cancer Institute of New Jersey, discusses the various aspects of the scientific educational value and aspects of the 2013 Annual Meeting of the American Society of Clinical Oncology, being held from May 31 to June 4, 2013 in Chicago, Ill.

Added by Editorial Team on May 31, 2013 at 12:00am — No Comments

Reolysin Meets Primary Endpoint for First Stage of Phase II Metastatic Melanoma Trial

A Phase II clinical trial in patients with metastatic melanoma using intravenous administration of a nonattenuated reovirus type-3 Dearing (RT3D; Reolysin(®, Oncolytics Biotech Inc) in combination with carboplatin and paclitaxel (NCT00984464) met primary endpoint for the first stage of the trial.  Reolysin is…


Added by Editorial Team on May 22, 2013 at 6:30pm — No Comments

Fewer Infections and Less Clotting Associated with Neutral Fluid Displacement Connector

The design of intravenous needleless connectors or NCs plays a substantial role in development of the potentially deadly hospital acquired-catheter related blood stream infection (HA-CRBSI) and the associated risk. Research on different types of needleless IV connectors led a Johns Hopkins cancer center to pilot a new "neutral pressure" IV connector. The results were presented at the at the 38th Annual Congress of the Oncology Nursing Society held April 25-28, 2013 in Washington, D.C.…


Added by Editorial Team on May 21, 2013 at 4:00pm — No Comments

Pfizer Discontinues Clinical Trial with Inotuzumab Ozogamicin in Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma (NHL)

Earlier today, Pfizer Inc. confirmed that it had discontinued a Phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of the investigational compound inotuzumab ozogamicin (CMC-544) in patients with relapsed or refractory CD22+ aggressive non-Hodgkin lymphoma (NHL) who are not candidates for intensive high-dose chemotherapy.

In this study, inotuzumab ozogamicin was administered on a once-a-month schedule in combination with rituximab…


Added by Editorial Team on May 20, 2013 at 6:00pm — No Comments

Phase III Trial of Regorafenib for the Treatment of Advanced Liver Cancer Starts Enrolling Patients

Earlier today, Bayer HealthCare announced that the company has started enrolling patients in an international Phase III trial to evaluate the efficacy and safety of regorafenib (Stivarga®) for the treatment of patients with hepatocellular carcinoma (HCC) who have progressed on sorafenib (Nexavar®, Bayer/Onyx) treatment. Regorafenib is an oral multi-kinase inhibitor that inhibits…


Added by Editorial Team on May 15, 2013 at 9:30pm — No Comments

Erlotinib is the First Personalized Medicine Approved for the Initial Treatment of People with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer

The U.S. Food and Drug Administration (FDA) has approved erlotinib tablets (Tarceva®; Genentech, Astellas Pharma), a once-daily, oral non-chemotherapy medicine for the initial or first-line treatment of people with metastatic non-small cell lung cancer (NSCLC) whose tumors have certain epidermal growth factor receptor (EGFR) activating mutations as detected by an FDA-approved test. In…


Added by Editorial Team on May 14, 2013 at 8:30pm — No Comments

Angelina Jolie: A Difficult Choice and A Courageous Decision

In an op-ed article titled "My Medical Choice" published earlier today in the New York Times, famed Hollywood actress Angelina Jolie writes that she, after learning that she carries a mutation of the BRCA1 gene which critically increases her risk of developing breast and ovarian cancer, made the decision to have a preventive or prophylactic double…


Added by Editorial Team on May 14, 2013 at 9:30am — 1 Comment

Enzastaurin Does Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma Study

Phase III clinical trial results from PRELUDE study, which explored the enzastaurin (Eli Lilly and Company; Lilly Oncology) as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL), failed to show a statistically significant increase compared to placebo…


Added by Peter Hofland, PhD on May 10, 2013 at 6:00am — No Comments

Study Evaluates Treatment of High Dose Aldesleukin + Vemurafenib in Patients with Metastatic Melanoma

A new multi-center trial of high dose Interleukin-2 (HD rIL-2; Aldesleukin for Injection/Proleukin®; Prometheus Laboratories Inc, San Diego, CA/Novartis Vaccines and Diagnostics, Emeryville, CA)[1] plus vemurafenib (Zelboraf®, Genentech/Roche) therapy in patients with BRAF V600 mutation-positive…


Added by Peter Hofland, PhD on May 9, 2013 at 10:00am — No Comments

New Diagnostic Test Effectively Predicts Rapid Metastatic Prostate Cancer (RMD) - Outperforms Existing Tools

Data presented today at the 2013 Annual Meeting for the American Urological Association by Johns Hopkins University School of Medicine researchers demonstrated that Decipher™ (GenomeDx Biosciences), a transformative genomic test that provides a readout of the risk of metastatic disease and disease progression for individual men with prostate cancer, predicted the onset of rapid metastatic disease (RMD) in patients following…


Added by Editorial Team on May 8, 2013 at 9:00pm — No Comments

UK Charity Calls for More Attention and Awareness for Bladder Cancer

Data from various cancer registries in the United Kingdom shows that Bladder Cancer is a common cancer among men and women in the United Kingdom, with 10.335 new cases diagnosed in 2008. [1][2][3][4] It is one of the most frequently diagnosed cancer of the urinary system and accounts for 1 in every 30 new cases. With 7,390 new cases diagnosed in 2008, is a the 4th most common cancer in men [5] and 11th in women (2,945 female cases), giving a male: female ration of…


Added by Peter Hofland, PhD on May 7, 2013 at 9:30pm — No Comments

Cryoablation Shows Promising Results in the Treatment of Breast Cancer

Date presented at the 2013 Conference of The American Society of Breast Surgeons (ASBrS) shows promising results for non-surgical cryoablation treatment of breast cancer. The results were presented by Eisuke Fukuma, M.D., Ph.D., Chairman and Director of Breast Center, Director of Breast Disease Kameda Medical Center in Kamogawa City, Chiba, Japan.

Cryoablation, also be called percutaneous ablation,…


Added by Peter Hofland, PhD on May 7, 2013 at 5:30pm — No Comments

Phase III Head-to-Head Study of Panitumumab Against Cetuximab in Metastatic Colorectal Cancer Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting

Results of the ASPECCT ('763) trial, a phase III head-to-head study evaluating panitumumab (Vectibix®; Amgen Inc.) versus cetuximab (Erbitux®; ImClone LLC/Eli Lilly and Company and Bristol-Myers Squibb Company) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint…


Added by Peter Hofland, PhD on May 7, 2013 at 3:00pm — No Comments

Physical Activity may help Reduce Breast Cancer Risk by Altering Estrogen Metabolism

Changes in estrogen breakdown, or metabolism, may be one of the mechanisms by which aerobic exercise lowers a woman’s breast cancer risk. A study discussing data that suggests that exercise influences estrogen metabolism was published earlier today in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Exercise boosts the immune system and helps keep a persons weight in…


Added by Editorial Team on May 7, 2013 at 1:00pm — No Comments

Sleep Disorders and Sleeping Problems Linked to Increased Risk for Prostate Cancer

Men who reported sleep disorders or ongoing sleeping problems, including difficulty falling asleep and staying asleep, had up to a twofold increased risk for prostate cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Sleep can often be a barometer of your overall health for both men and women. In many cases, people in good health…


Added by Editorial Team on May 7, 2013 at 12:30pm — No Comments

Rare Mutation Increases Risks of Osteoporosis and Certain Cancers

Scientists from the National University Hospital of Iceland and the University of Iceland together with researchers at deCODE genetics and Illumina, reported today in the journal Nature[1] that they…


Added by Editorial Team on May 5, 2013 at 9:00pm — No Comments

Expense and Unaffordable Leukemia Treatment May Harm Patients

An article supported by nearly 120 leukemia specialists published today in Blood, the most cited peer-reviewed publication in the field of hematology published by the American Society of Hematology, increases in costs of treatments for chronic myeloid leukemia…


Added by Editorial Team on May 5, 2013 at 3:00pm — No Comments

Monthly Archives














Register for free to view all the Onco'Zine - The International Oncology Network content:


Onco'Zine is present here

Bookmark / Share



© 2017   Created by Peter Hofland, PhD.   Powered by

Badges  |  Report an Issue  |  Terms of Service

Find us on Google+